By F. Bandello, M. Battaglia Parodi, A.J. Augustin, P. Iacono, R.O. Schlingemann, U. Schmidt-Erfurth, F.D. Verbraak
The improvement of remedy with anti-angiogenics or vascular endothelial progress issue inhibitors (anti-VEGF) has marked the start of a brand new period in neovascularization and macular edema remedy. Its major ambitions are the inhibition of development and improvement of latest vessels besides the relief of vascular permeability. the benefits over traditional laser photocoagulation are glaring as laser therapy continually leaves scars and explanations a retinal sensitivity deterioration. beginning with an summary of remedy ideas, this quantity covers all features of anti-VEGF remedy for ophthalmological issues. specifically, particular chapters are devoted to age-related macular degeneration, degenerative myopia, angioid streaks, inflammatory ailments, hereditary dystrophies, retinal vein occlusion, diabetic retinopathy, ocular tumors, in addition to anterior section neovascularization. The booklet provides an replace at the software of anti-VEGF in ocular illnesses to basic ophthalmologists in addition to retina experts.
Read Online or Download Anti-vegf (Developments in Ophthalmology) PDF
Best ophthalmology books
This quantity from the necessities in Ophthalmology sequence offers fresh advancements within the analysis and remedy of corneal illness. Its goal isn't really to exchange the suitable textbooks, yet to function a bridge among the first and tertiary literature. This well-structured quantity covers the subsequent major subject matters: Confocal microscopy of the cornea.
The vast box of neuro-ophthalmology encompasses lesions of either the afferent and efferent pathways, which could consequence from quite a few etiologies: tumoral, paraneoplastic, vascular, inflammatory, infectious, or hereditary, simply to identify a number of. This quantity of necessities in Ophthalmology is devoted to the assessment of latest advancements in neuro-ophthalmology, together with these in analysis, body structure, investigations or healing strategies.
Offers useful medical information regarding the administration of this illness. Covers crucial medical manifestations, diagnostic applied sciences and healing modalities, and studies fresh advancements within the pathogenesis and administration of glaucoma.
Electronic fundus photos can successfully diagnose glaucoma and diabetes retinopathy, whereas infrared imaging can express adjustments within the vascular tissues. Likening the attention to the traditional digital camera, picture research and Modeling in Ophthalmology explores the applying of complicated photo processing in ocular imaging.
Extra resources for Anti-vegf (Developments in Ophthalmology)
Ophthalmology 2008;115: e39–e46. 95 Kiss CG, Geitzenauer W, Simader C, et al: Evaluation of ranibizumab-induced changes in high-resolution optical coherence tomographic retinal morphology and their impact on visual function. Invest Ophthalmol Vis Sci 2009;50:2376–2383. 96 Bakri SJ, Kitzmann AS: Retinal pigment epithelial tear after intravitreal ranibizumab. Am J Ophthalmol 2007;143:505–507. 97 Kiss C, Michels S, Prager F, et al: Retinal pigment epithelium tears following intravitreal ranibizumab therapy.
Verteporfin PDT was selected as the compared treatment in the latter study because it has been shown to slow the progression of vision loss in patients with this typically more aggressive type of lesion [60, 61], and was the standard treatment when this study was initiated. These two studies (described in detail below) were pivotal evaluations of the 26 Schmidt-Erfurth · Pollreisz · Mitsch · Bolz Fig. 1. Ranibizumab (Lucentis®): a humanized monoclonal antibody fragment (Fab) directed against VEGF produced in Escherichia coli.
Toxicol Pathol 1999; 27:536–544. 36 Heiduschka P, Fietz H, Hofmeister S, et al: Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48:2814–2823. 37 Shahar J, Avery RL, Heilweil G, et al: Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006;26:262–269. 38 Michels S, Rosenfeld PJ, Puliafito CA, et al: Systemic bevacizumab (Avastin) therapy for neovascular agerelated macular degeneration 12-week results of an uncontrolled open-label clinical study.